Background: In the last two decades, extreme obesity and its comorbidities have often been treated with bariatric
surgery.
Objective: Our goal was to compare the levels of GLP-1 in individuals who are severely obese three months after
undergoing any of the three more frequent bariatric methods: sleeve gastrectomy (SG), Roux en Y gastric bypass
(RYGB), or intragastric balloon (IGB).
Patients and Methods: This is prospective research being done at Benha University Hospital for people with obesity
and type 2 diabetes who have been recruited 3 months prior to having any bariatric surgeries. Patients were subjected
to measurement of WC, BMI and laboratory assay of HbA1c, fasting plasma glucose (FPG), fasting insulin, HOMAIR, ALT, AST, glucagon-like peptide-1 (GLP-1) and lipid profile before and after 3 months of procedures.
Results: There was significant improvement of FPG, and HbA1c in RYGB operation in comparison with other bariatric
procedures. Fasting insulin was substantially lower in the RYGB surgery than the in SG and IGB (p ˂ 0.05) with
substantial improvements of HOMA-IR for RYGB surgery (p ˂ 0.05). In RYGB surgery, there was highly substantial
increase in GLP-1 levels compared to SG and IGB procedures (p